Evaluation of fosaprepitant-associated hypersensitivity reactions at a National Cancer Center.
Catherine Michelle LairdAshley E GlodeKerry A SchwarzElaine T LamCindy L O'BryantPublished in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2020)
The incidence of HSRs to fosaprepitant at our institution was found to be consistent with the <1% incidence currently noted in literature. Based on these findings, opportunities have been identified for education on fosaprepitant-associated HSRs, proper documentation and patient-specific precautions.
Keyphrases